How Canadian Cannabis Firms Are Cracking Global Markets

Six years after legalization, Canada's cannabis industry looks nothing like the one investors pitched in 2018. Domestic prices have collapsed under oversupply, dozens of licensed producers have shut down or been absorbed, and the survivors have quietly rebuilt their businesses around a different customer entirely: patients and buyers thousands of miles away. Companies like Tilray, Canopy Growth, and Aurora Cannabis now generate a meaningful share of revenue from Germany, Australia, Israel, and the UK rather than Toronto or Vancouver.

The shift didn't happen by accident. It's the product of years spent chasing EU-GMP certification, negotiating with foreign regulators, and figuring out how to move a federally illegal-in-most-places plant across borders without running afoul of customs law in a dozen jurisdictions at once.

Why Canadian Producers Looked Abroad

Photo by Diego Barros via Pexels.

Canada legalized recreational cannabis in October 2018 with a licensing system that let almost anyone with capital and a Health Canada permit build a grow operation. Hundreds did. By 2020, the country had far more licensed cultivation square footage than its 4 million or so adult consumers could ever buy through, and wholesale flower prices fell from roughly $8-10 a gram at the outset to under $2 in many provincial supply deals by 2022.

That oversupply turned into an asset once companies realized they could route surplus, high-quality product to countries just beginning to build medical cannabis programs. Germany, Australia, and Israel all needed reliable, quality-controlled supply and didn't have the domestic cultivation base to meet it. Canadian producers, many of whom had already built pharmaceutical-grade facilities to satisfy Health Canada's rules, were positioned to fill that gap faster than local growers in those markets.

EU-GMP Certification Is the Real Barrier to Entry

Photo by Glsun Mall via Unsplash.

The single biggest hurdle for any Canadian exporter isn't growing good cannabis -- it's getting certified to sell it in Europe. EU Good Manufacturing Practice certification requires a facility to meet pharmaceutical manufacturing standards: validated cleanrooms, documented batch records, contamination controls, and inspection by a qualified person recognized under EU law. Health Canada's own licensing rules don't automatically satisfy this; companies typically need a separate audit process, often costing millions of dollars and taking a year or more to pass.

Firms like Tilray (through its European subsidiary), Peace Naturals, and Canopy Growth's former Canadian facilities pursued EU-GMP specifically to sell into Germany, which has run a prescription-based medical cannabis system since 2017 covered in part by statutory health insurance. Without that certification, a Canadian grower simply cannot legally place flower or extracts into the German pharmacy supply chain, regardless of product quality.

Israel and Australia run their own parallel approval systems -- Israel's Medical Cannabis Unit (IMCU) and Australia's Therapeutic Goods Administration -- each with separate import permits, testing requirements, and paperwork that has to be renegotiated on a country-by-country basis. There's no single passport that gets a Canadian export into every market at once.

Germany Became the Proving Ground

Photo by MART PRODUCTION via Pexels.

Germany is the market that matters most right now, and not just because of its population. Since April 2024, Germany decriminalized possession of small amounts and allowed limited home cultivation and cannabis clubs, but the medical prescription channel -- the one Canadian companies actually sell into -- has grown even faster since a separate 2024 reform removed cannabis from the country's narcotics law for medical purposes, cutting red tape for doctors writing prescriptions.

Tilray's German subsidiary, Aphria RX (formerly CC Pharma before consolidation), has been one of the larger importers of Canadian-grown medical flower into German pharmacies for years. Canopy Growth has supplied German buyers through its Spectrum Therapeutics brand. Demand has been strong enough that Canadian growers now compete there with Portuguese, Danish, and increasingly domestic German cultivators as more EU-based EU-GMP facilities come online.

That competition is exactly why the early movers matter. Companies that secured EU-GMP certification and distribution contracts in 2019 and 2020 built relationships with German pharmacy wholesalers before the market got crowded. Latecomers now face tougher pricing and slower approval queues.

Australia and Israel: Smaller Markets, Established Buyers

Photo by Nataliya Vaitkevich via Pexels.

Australia's medical cannabis system, run through the TGA's Special Access Scheme and Authorised Prescriber pathway, has grown into a market of several hundred thousand patients since 2016, and a good portion of the flower and oil supplying it arrives from Canada. Companies including Aurora Cannabis, which operates its own Australian subsidiary, and Canopy Growth have used Australia as a foothold in the Asia-Pacific region more broadly, betting that Australian approval pathways will eventually smooth entry into countries like Thailand and parts of Southeast Asia that are loosening their own rules.

Israel occupies a different niche. It has one of the oldest medical cannabis research traditions in the world, dating back to Dr. Raphael Mechoulam's identification of THC's structure in the 1960s, and its domestic cultivation industry is sophisticated. Canadian exporters there tend to supply specific genetics or extracts rather than bulk flower, filling gaps rather than competing head-on with Israeli growers who already serve roughly 100,000 registered patients through the Ministry of Health's program.

The Logistics Nobody Talks About

Photo by Harald Hechler via Pexels.

Getting cannabis across an international border legally involves paperwork that has nothing to do with THC content. Each shipment needs an import permit issued by the destination country's regulator, matched against an export permit from Health Canada, plus documentation tied to the 1961 Single Convention on Narcotic Drugs, which still classifies cannabis as a controlled substance requiring government-to-government authorization for cross-border trade.

Shipping itself is a narrower problem than people expect. Most international couriers and airlines won't touch cannabis product because of liability and mixed jurisdictional rules along transit routes, so exporters rely on a small number of specialized logistics firms with experience handling controlled pharmaceutical shipments -- often the same companies that move vaccines and other temperature-sensitive medicines. Cold-chain handling, tamper-evident packaging, and chain-of-custody documentation all add cost before a single gram reaches a foreign pharmacy shelf.

The Canadian companies still standing five years after the oversupply crash are, almost without exception, the ones that treated export markets as the actual business rather than a side hustle. Domestic Canadian retail remains a low-margin, price-competitive slog. Germany, Australia, and Israel pay better and reward the regulatory groundwork that scared off less patient competitors.

None of this is finished business. Germany's market keeps shifting as EU cultivation capacity grows, Australia's patient numbers keep climbing, and new markets -- Poland, Czechia, parts of Latin America -- are opening approval pathways of their own. The companies that figure out how to replicate their EU-GMP playbook in the next country first will likely be the ones still around for the next round of consolidation. Rules on cannabis import and export change often and vary by country, so anyone tracking this space, whether as an investor or a patient, should check current regulations directly with the relevant national authority rather than relying on last year's framework.

Photo by Wolfgang Weiser via Pexels.